These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunoscintigraphic localization of inflammatory lesions: concept, radiolabelling and in vitro testing of a granulocyte specific antibody. Andres RY; Schubiger PA; Tiefenauer L; Seybold K; Locher JT; Mach JP; Buchegger F Eur J Nucl Med; 1988; 13(11):582-6. PubMed ID: 3350035 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726 [TBL] [Abstract][Full Text] [Related]
5. Imaging of inflammatory and infectious lesions after injection of radioiodinated monoclonal anti-granulocytes antibodies. Locher JT; Seybold K; Andres RY; Schubiger PA; Mach JP; Buchegger F Nucl Med Commun; 1986 Sep; 7(9):659-70. PubMed ID: 3490648 [TBL] [Abstract][Full Text] [Related]
6. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Rosenblum MG; Murray JL; Haynie TP; Glenn HJ; Jahns MF; Benjamin RS; Frincke JM; Carlo DJ; Hersh EM Cancer Res; 1985 May; 45(5):2382-6. PubMed ID: 3986780 [TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy. Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731 [TBL] [Abstract][Full Text] [Related]
9. Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I. Badger CC; Davis J; Nourigat C; Wu ZM; Hui TE; Fisher DR; Shulman H; Appelbaum FR; Eary JF; Krohn KA Cancer Res; 1991 Nov; 51(21):5921-8. PubMed ID: 1682038 [TBL] [Abstract][Full Text] [Related]
10. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
11. Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies. Rosenblum MG; Murray JL; Lamki L; David G; Carlo D Cancer Chemother Pharmacol; 1987; 20(1):41-7. PubMed ID: 3621452 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody hapten radiopharmaceutical delivery. Goodwin DA; Mears CF; McTigue M; David GS Nucl Med Commun; 1986 Aug; 7(8):569-80. PubMed ID: 3095721 [TBL] [Abstract][Full Text] [Related]
13. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497 [TBL] [Abstract][Full Text] [Related]
14. In vivo labelling of granulocytes using 123I-tagged anti-granulocyte antibodies. Seybold K Nucl Med Commun; 1988 Oct; 9(10):745-52. PubMed ID: 3211433 [TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303 [TBL] [Abstract][Full Text] [Related]
16. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230 [TBL] [Abstract][Full Text] [Related]
18. Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. Virgolini I; Kurtaran A; Leimer M; Smith-Jones P; Agis H; Angelberger P; Kletter K; Valent P; Linkesch W; Eichler HG J Nucl Med; 1997 Sep; 38(9):1475-81. PubMed ID: 9293812 [TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762 [TBL] [Abstract][Full Text] [Related]
20. Radiation dosimetry of a 99mTc-labeled IgM murine antibody to CD15 antigens on human granulocytes. Mozley PD; Stubbs JB; Dresel SH; Barraclough ED; Smith T; Patel M; Finkelman C; Sparks RB; Thakur ML; Mathur A; Alavi A J Nucl Med; 1999 Apr; 40(4):625-30. PubMed ID: 10210221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]